CytomX Therapeutics Reports Sharp Q1 Revenue Decline & Net Loss, Boosts Liquidity with $234M Offering to Extend Runway

summarizeSummary

CytomX Therapeutics reported an 80% Q1 revenue drop and a net loss, but secured $234.2 million from a public offering, extending its cash runway to H2 2028 amidst collaboration terminations and ongoing clinical trials.

check_boxKey Events

• Significant Revenue Decline and Net Loss

  Q1 2026 revenue decreased by 80% year-over-year to $10.3 million, resulting in a net loss of $18.2 million, a substantial swing from a net income of $23.5 million in Q1 2025.

• Successful $234.2M Equity Offering

  The company completed an underwritten public offering in March 2026, raising approximately $234.2 million in net proceeds by issuing common stock and pre-funded warrants.

• Extended Cash Runway

  The recent financing has extended the company's cash, cash equivalents, and short-term investments to $346.7 million as of March 31, 2026, and is expected to fund operations into at least the second half of 2028.

• Collaboration Terminations and Pauses

  Astellas and Bristol Myers Squibb terminated their collaboration agreements in Q1 2026 and May 2026, respectively, while Moderna paused its program due to budget considerations, significantly impacting future collaboration revenue.

auto_awesomeAnalysis

CytomX Therapeutics reported a significant financial downturn for Q1 2026, with revenue plummeting 80% year-over-year to $10.3 million and a net loss of $18.2 million, compared to a net income in the prior year. This decline was primarily driven by the termination of collaboration agreements with Astellas and Bristol Myers Squibb, and a pause in activities with Moderna due to budget considerations. Despite the poor operational results, the company successfully completed an underwritten public offering in March 2026, raising approximately $234.2 million in net proceeds. This substantial capital infusion has significantly improved the company's liquidity, extending its cash runway into at least the second half of 2028. The company also provided updates on its clinical pipeline, with Varseta-M and CX-801 advancing in Phase 1 trials and plans for a potential registrational study for Varseta-M in H1 2027. While the operational performance is concerning due to collaboration setbacks, the successful financing provides critical funding for ongoing clinical development and extends the company's operational timeline.